{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:48Z","timestamp":1794962988515,"version":"4.9.1"},"reference-count":162,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MoonLake Immunotherapeutics AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1\u20132%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal\/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-\u03b1 and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and\/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-\u03b1 antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)\/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic \u2018window of opportunity\u2019; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.<\/jats:p>","DOI":"10.1093\/bjd\/ljad345","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T11:07:26Z","timestamp":1694862446000},"page":"149-162","source":"Crossref","is-referenced-by-count":121,"title":["Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape"],"prefix":"10.1093","volume":"190","author":[{"given":"James G","family":"Krueger","sequence":"first","affiliation":[{"name":"Laboratory of Investigative Dermatology, The Rockefeller University , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frew","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research , Sydney , Australia"},{"name":"Department of Dermatology, Liverpool Hospital , Sydney , Australia"},{"name":"University of New South Wales , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B E","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital , Roskilde , Denmark"},{"name":"Health Sciences Faculty, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B","family":"Kimball","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School , Boston, MA , USA"},{"name":"Beth Israel Deaconess Medical Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Charles Department of Dermatology, St Vincent\u2019s University Hospital , Dublin , Ireland"},{"name":"Charles Institute of Dermatology, University College Dublin , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G","family":"Bechara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum , Bochum , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Navrazhina","sequence":"additional","affiliation":[{"name":"Laboratory of Investigative Dermatology, The Rockefeller University , New York, NY , USA"},{"name":"Weill Cornell\/Rockefeller\/Sloan Kettering Tri-Institutional MD-PhD Program , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol","family":"Prens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, Institute for Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf , Germany"},{"name":"MoonLake Immunotherapeutics AG , Zug , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Cullen","sequence":"additional","affiliation":[{"name":"MoonLake Immunotherapeutics AG , Zug , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7689-4130","authenticated-orcid":false,"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Centre, Department of Dermatology, Venereology and Allergology and Institute of Medical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"key":"2024012322594400100_ljad345-B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B2","doi-asserted-by":"crossref","first-page":"875492","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024012322594400100_ljad345-B3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.21293","article-title":"The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed","volume":"186","author":"Kearney","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjd.20954","article-title":"New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities","volume":"186","author":"Prens","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024012322594400100_ljad345-B6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"issue":"5 Suppl. 1","key":"2024012322594400100_ljad345-B7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","article-title":"Hidradenitis suppurativa: epidemiology and scope of the problem","volume":"73","author":"Jemec","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B8","first-page":"2","article-title":"Global prevalence of hidradenitis suppurativa and geographical variation \u2013 systematic review and meta-analysis","volume-title":"Biomed Dermatol","author":"Phan","year":"2020"},{"key":"2024012322594400100_ljad345-B9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjmed.2022.09.025","article-title":"A practical guide for primary care providers on timely diagnosis and comprehensive care strategies for hidradenitis suppurativa","volume":"136","author":"Garg","year":"2023","journal-title":"Am J Med"},{"key":"2024012322594400100_ljad345-B10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jamadermatol.2019.0478","article-title":"Distribution of self-reported hidradenitis suppurativa age at onset","volume":"155","author":"Naik","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B12","doi-asserted-by":"crossref","first-page":"e29-32","DOI":"10.1016\/j.jaad.2021.02.075","article-title":"Late-onset hidradenitis suppurativa: a cluster analysis of the National Italian Registry IRHIS","volume":"85","author":"Cazzaniga","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"2024012322594400100_ljad345-B14","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024012322594400100_ljad345-B15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamadermatol.2017.6058","article-title":"Association of hidradenitis suppurativa with body image","volume":"154","author":"Schneider-Burrus","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2019.11.068","article-title":"Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis","volume":"83","author":"Patel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B18","doi-asserted-by":"crossref","first-page":"e171-7","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/PROM.S174299","article-title":"An update on health-related quality of life and patient-reported outcomes in hidradenitis suppurativa","volume":"11","author":"Mac Mahon","year":"2020","journal-title":"Patient Relat Outcome Meas"},{"key":"2024012322594400100_ljad345-B20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaad.2011.10.024","article-title":"Profound disturbances of sexual health in patients with acne inversa","volume":"67","author":"Kurek","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B21","first-page":"743","article-title":"Depression is a frequent co-morbidity in patients with acne inversa","volume":"11","author":"Kurek","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024012322594400100_ljad345-B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2147\/CCID.S180036","article-title":"Perspectives on perceived stigma and self-stigma in patients with hidradenitis suppurativa","volume":"12","author":"Koumaki","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2024012322594400100_ljad345-B23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/bjd\/ljac027","article-title":"The impact of hidradenitis suppurativa on professional life","volume":"188","author":"Schneider-Burrus","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B24","doi-asserted-by":"crossref","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","article-title":"Increased prevalence of metabolic syndrome in patients with acne inversa","volume":"7","author":"Sabat","year":"2012","journal-title":"PLOS ONE"},{"key":"2024012322594400100_ljad345-B25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaad.2016.03.025","article-title":"Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS)","volume":"75","author":"Gonzalez-Lopez","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B27","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/bjd.17578","article-title":"Substantially reduced life expectancy in patients with hidradenitis suppurativa: a Finnish nationwide registry study","volume":"180","author":"Tiri","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B28","doi-asserted-by":"crossref","first-page":"15250","DOI":"10.3390\/ijms232315250","article-title":"The role of hormones in hidradenitis suppurativa: a systematic review","volume":"23","author":"Abu Rached","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024012322594400100_ljad345-B29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/exd.14234","article-title":"Mechanical forces and hidradenitis suppurativa","volume":"30","author":"Boer","year":"2021","journal-title":"Exp Dermatol"},{"key":"2024012322594400100_ljad345-B30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094874","article-title":"Epigenetic mechanisms of epidermal differentiation","volume":"23","author":"Moltrasio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024012322594400100_ljad345-B31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091168","article-title":"Insights into the pathogenesis of HS and therapeutical approaches","volume":"9","author":"Rosi","year":"2021","journal-title":"Biomedicines"},{"key":"2024012322594400100_ljad345-B32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024012322594400100_ljad345-B34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40257-021-00667-8","article-title":"Medical management of hidradenitis suppurativa with non-biologic therapy: what\u2019s new?","volume":"23","author":"Ghanian","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024012322594400100_ljad345-B35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40257-019-00491-1","article-title":"Laser and light-based treatment modalities for the management of hidradenitis suppurativa","volume":"21","author":"Lyons","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2024012322594400100_ljad345-B36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A Comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"2024012322594400100_ljad345-B37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.08.010","article-title":"Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa","volume":"84","author":"Hessam","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2024012322594400100_ljad345-B38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American Clinical Management Guidelines for Hidradenitis Suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B39","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"2024012322594400100_ljad345-B40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-5945-12-9","article-title":"A review of wide surgical excision of hidradenitis suppurativa","volume":"12","author":"Alharbi","year":"2012","journal-title":"BMC Dermatol"},{"key":"2024012322594400100_ljad345-B41","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis suppurativa: where we are and where we are going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"issue":"5 Suppl. 1","key":"2024012322594400100_ljad345-B42","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","article-title":"Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis","volume":"73","author":"Mehdizadeh","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ced.14054","article-title":"Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model","volume":"45","author":"Quartey","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2024012322594400100_ljad345-B44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jid.2020.02.014","article-title":"Ex vivo models and interpretation of mechanistic studies in hidradenitis suppurativa","volume":"140","author":"Frew","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024012322594400100_ljad345-B46","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-Handel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","article-title":"Association of hidradenitis suppurativa with T helper 1\/T helper 17 phenotypes: a semantic map analysis","volume":"154","author":"Thomi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5 Suppl. 1","key":"2024012322594400100_ljad345-B50","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: an update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/exd.12793","article-title":"The bacteriology of hidradenitis suppurativa: a systematic review","volume":"24","author":"Ring","year":"2015","journal-title":"Exp Dermatol"},{"key":"2024012322594400100_ljad345-B52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2024012322594400100_ljad345-B53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota Cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024012322594400100_ljad345-B54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"2024012322594400100_ljad345-B55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B56","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"2024012322594400100_ljad345-B57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024012322594400100_ljad345-B58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2024012322594400100_ljad345-B59","author":"European Medicines Agency"},{"key":"2024012322594400100_ljad345-B60","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"2024012322594400100_ljad345-B61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B62","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2024012322594400100_ljad345-B63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B64","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B65","author":"NCT03628924"},{"key":"2024012322594400100_ljad345-B66","author":"NCT03926169"},{"key":"2024012322594400100_ljad345-B67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-08360-9","article-title":"The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties","volume":"7","author":"Goepfert","year":"2017","journal-title":"Sci Rep"},{"key":"2024012322594400100_ljad345-B68","doi-asserted-by":"crossref","first-page":"e90284","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLOS ONE"},{"key":"2024012322594400100_ljad345-B69","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200939687","article-title":"The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis","volume":"39","author":"Wolk","year":"2009","journal-title":"Eur J Immunol"},{"key":"2024012322594400100_ljad345-B70","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B71","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.12236","article-title":"Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin","volume":"168","author":"Keijsers","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B72","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B73","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B76","doi-asserted-by":"crossref","first-page":"e139930","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"2024012322594400100_ljad345-B77","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B78","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","article-title":"Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis","volume":"69","author":"Rumberger","year":"2020","journal-title":"Inflamm Res"},{"key":"2024012322594400100_ljad345-B79","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B80","author":"Kimball"},{"key":"2024012322594400100_ljad345-B81","author":"NCT05322473"},{"key":"2024012322594400100_ljad345-B82","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"2024012322594400100_ljad345-B83","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A\/F nanobody, in moderate-to-severe psoriasis","volume":"81","author":"Svecova","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B84","author":"MoonLake Immunotherapeutics"},{"key":"2024012322594400100_ljad345-B85","author":"NCT05355805"},{"key":"2024012322594400100_ljad345-B86","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp Mol Med"},{"key":"2024012322594400100_ljad345-B87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1alpha for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B90","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B91","author":"NCT04988308"},{"key":"2024012322594400100_ljad345-B92","first-page":"17","article-title":"Spesolimab for hidradenitis suppurativa: proof-of-concept study","author":"Alavi","year":"2023"},{"key":"2024012322594400100_ljad345-B93","author":"NCT05139602"},{"key":"2024012322594400100_ljad345-B94","author":"NCT03972280"},{"key":"2024012322594400100_ljad345-B95","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/exd.14092","article-title":"Beyond antibodies: B cells in hidradenitis suppurativa: bystanders, contributors or therapeutic targets?","volume":"29","author":"Frew","year":"2020","journal-title":"Exp Dermatol"},{"key":"2024012322594400100_ljad345-B96","doi-asserted-by":"crossref","first-page":"3139932","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-alpha therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"2024012322594400100_ljad345-B97","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of -concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B98","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B99","doi-asserted-by":"crossref","first-page":"e0203672","DOI":"10.1371\/journal.pone.0203672","article-title":"Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature","volume":"13","author":"Hoffman","year":"2018","journal-title":"PLOS ONE"},{"key":"2024012322594400100_ljad345-B100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"2024012322594400100_ljad345-B101","author":"Kirby"},{"key":"2024012322594400100_ljad345-B102","author":"NCT05620823"},{"key":"2024012322594400100_ljad345-B103","author":"NCT05620836"},{"key":"2024012322594400100_ljad345-B104","author":"Kimball"},{"key":"2024012322594400100_ljad345-B105","author":"NCT05216224"},{"key":"2024012322594400100_ljad345-B106","first-page":"413","article-title":"Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?","volume":"179","author":"Kanni","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B107","author":"NCT03487276"},{"key":"2024012322594400100_ljad345-B108","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.jid.2021.03.037","article-title":"No evident systemic terminal complement pathway activation in hidradenitis suppurativa","volume":"141","author":"Prens","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B109","author":"NCT03852472"},{"key":"2024012322594400100_ljad345-B110","author":"ChemoCentryx"},{"key":"2024012322594400100_ljad345-B111","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1159\/000521263","article-title":"Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation","volume":"238","author":"Marzano","year":"2022","journal-title":"Dermatology"},{"key":"2024012322594400100_ljad345-B112","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/jdv.17095","article-title":"Full exome sequencing of 11 families with hidradenitis suppurativa","volume":"35","author":"Theut Riis","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024012322594400100_ljad345-B113","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jid.2012.372","article-title":"gamma-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis","volume":"133","author":"Pink","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B114","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042278","article-title":"Variant enrichment analysis to explore pathways functionality in complex autoinflammatory skin disorders through whole exome sequencing analysis","volume":"23","author":"Brandao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024012322594400100_ljad345-B115","doi-asserted-by":"crossref","first-page":"2450401","DOI":"10.1155\/2017\/2450401","article-title":"The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa","volume":"2017","author":"Jimenez-Gallo","year":"2017","journal-title":"Mediators Inflamm"},{"key":"2024012322594400100_ljad345-B116","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa","volume":"103","author":"Jimenez-Gallo","year":"2018","journal-title":"Cytokine"},{"key":"2024012322594400100_ljad345-B117","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12234","article-title":"Myeloid marker S100A8\/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?","volume":"168","author":"Wieland","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B118","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13547500903075218","article-title":"Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging","volume":"14","author":"Matusiak","year":"2009","journal-title":"Biomarkers"},{"key":"2024012322594400100_ljad345-B119","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/bjd.15424","article-title":"Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa\/hidradenitis suppurativa","volume":"177","author":"Wolk","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B120","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In-depth analysis of the hidradenitis suppurativa serum proteome identifies distinct inflammatory subtypes","volume":"141","author":"Navrazhina","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B121","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B122","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review","volume":"158","author":"Der Sarkissian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024012322594400100_ljad345-B123","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jid.2020.08.032","article-title":"Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the national Italian registry IRHIS","volume":"141","author":"Cazzaniga","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B124","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024012322594400100_ljad345-B125","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study","volume":"133","author":"Canoui-Poitrine","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B126","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000518965","article-title":"Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large Dutch cohort","volume":"238","author":"Dudink","year":"2022","journal-title":"Dermatology"},{"key":"2024012322594400100_ljad345-B127","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00403-020-02149-z","article-title":"Sub-classification of hidradenitis suppurativa: a cross-sectional study","volume":"314","author":"Thorlacius","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"2024012322594400100_ljad345-B128","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2024012322594400100_ljad345-B129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000526069","article-title":"Demographic gaps and requirements for participation: a systematic review of clinical trial designs in hidradenitis suppurativa","volume":"239","author":"James","year":"2023","journal-title":"Dermatology"},{"issue":"5 Suppl. 1","key":"2024012322594400100_ljad345-B130","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"van der Zee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B131","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6\u2005months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024012322594400100_ljad345-B132","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B133","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B134","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.14448","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab","volume":"46","author":"Frew","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2024012322594400100_ljad345-B135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B136","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjd.21821","article-title":"Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa","volume":"187","author":"Hasan","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B137","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B138","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B139","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"2024012322594400100_ljad345-B140","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B141","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2024012322594400100_ljad345-B142","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/j.jaad.2020.07.040","article-title":"High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?","volume":"83","author":"Kimball","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594400100_ljad345-B143","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jdv.14007","article-title":"Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"31","author":"Puig","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024012322594400100_ljad345-B144","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI","volume":"28","author":"Elewski","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2024012322594400100_ljad345-B145","author":"Kimball"},{"key":"2024012322594400100_ljad345-B146","author":"NCT03713619"},{"key":"2024012322594400100_ljad345-B147","author":"NCT03713632"},{"key":"2024012322594400100_ljad345-B148","author":"NCT03827798"},{"key":"2024012322594400100_ljad345-B149","author":"NCT04762277"},{"key":"2024012322594400100_ljad345-B150","author":"NCT05819398"},{"key":"2024012322594400100_ljad345-B151","author":"NCT04493502"},{"key":"2024012322594400100_ljad345-B152","author":"NCT05103423"},{"key":"2024012322594400100_ljad345-B153","author":"NCT05849922"},{"key":"2024012322594400100_ljad345-B154","author":"NCT04430855"},{"key":"2024012322594400100_ljad345-B155","author":"Kimball"},{"key":"2024012322594400100_ljad345-B156","author":"NCT05635838"},{"key":"2024012322594400100_ljad345-B157","author":"NCT05020730"},{"key":"2024012322594400100_ljad345-B158","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther (Heidelb"},{"key":"2024012322594400100_ljad345-B159","author":"NCT04856930"},{"key":"2024012322594400100_ljad345-B160","author":"AnaptysBio"},{"key":"2024012322594400100_ljad345-B161","author":"NCT04019041"},{"key":"2024012322594400100_ljad345-B162","author":"NCT05348681"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad345\/53669529\/ljad345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/149\/56345069\/ljad345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/149\/56345069\/ljad345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T18:08:36Z","timestamp":1706033316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/2\/149\/7275339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":162,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,16]]},"published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad345","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,9,16]]}}}